Experimental study of a rabies vaccine from sheep brain tissue inactivated with UV rays
A 1975 Soviet study evaluated a rabies vaccine prepared from infected sheep brain tissue and inactivated with ultraviolet irradiation, comparing its antigenic response in rabbits with Fermi-type and tissue-culture vaccines.
What the study did and found
N. A. Pospeeva and colleagues' 1975 article “Experimental study of a rabies vaccine from sheep brain tissue inactivated with UV rays” described a rabies vaccine made from a 20% suspension of sheep brain infected with fixed rabies virus and inactivated by ultraviolet irradiation. The treated material was freeze-dried and its antigenicity tested in rabbits alongside a Fermi-type vaccine and a Soviet tissue-culture vaccine. The abstract reports that the UV-inactivated preparation produced a maximum mean neutralizing-antibody titre of 341, compared with 158 and 129 for the two comparator vaccines. The work was an animal comparative study and reported high antigenic activity. These results concerned experimental immunogenicity in animals, not clinical protection in humans.
Why it is cited
The paper is relevant to the history of rabies-vaccine development because it documents an attempt to improve an older neural-tissue vaccine by changing the inactivation method. It also provides a direct comparison with other vaccine types in use at the time.
Modern rabies-vaccine practice has moved away from neural-tissue vaccines such as preparations made from sheep or other animal brains. WHO states that nerve-tissue vaccines are less immunogenic and cause more severe adverse reactions than modern cell-culture or embryonated-egg vaccines, and recommends that their production and use be discontinued. The 1975 study's rabbit antibody results therefore remain historical evidence about one experimental formulation rather than support for current human vaccination practice.
The topic today
Current human rabies prevention uses purified, inactivated vaccines produced in cell culture or embryonated eggs for pre-exposure and post-exposure prophylaxis. Vaccine quality is assessed with modern standards for production, inactivation, potency and safety, while post-exposure management also depends on exposure category and, when indicated, rabies immunoglobulin. The historical shift from neural tissue to cell-based production reflects major advances in vaccine safety, consistency and clinical use.